United Therapeutics Corporation (UTHR) Receiving Somewhat Favorable News Coverage, Report Shows
News articles about United Therapeutics Corporation (NASDAQ:UTHR) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. United Therapeutics Corporation earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.7694241882299 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Martine A. Rothblatt Sells 1,232 Shares of United Therapeutics Corporation (UTHR) Stock (americanbankingnews.com)
- First Week of UTHR October 20th Options Trading (nasdaq.com)
- United Therapeutics (UTHR) Reports FREEDOM-EV Study Of Orenitram To Continue As Planned Following Interim Analysis (streetinsider.com)
- United Therapeutics Announces FREEDOM-EV Study Of Orenitram® To Continue As Planned Following Interim Analysis (finance.yahoo.com)
- Christopher Causey Sells 580 Shares of United Therapeutics Corporation (UTHR) Stock (americanbankingnews.com)
Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 120.82 on Friday. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The company has a market cap of $5.25 billion, a price-to-earnings ratio of 14.01 and a beta of 1.52. The firm has a 50 day moving average price of $130.10 and a 200-day moving average price of $130.86.
United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The firm had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. During the same quarter in the previous year, the business earned $4.42 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Corporation will post $10.09 earnings per share for the current year.
A number of research firms have recently commented on UTHR. UBS AG reissued a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a report on Thursday, July 6th. ValuEngine upgraded United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. BidaskClub lowered United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Jefferies Group LLC restated a “sell” rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Finally, Zacks Investment Research lowered United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Six investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. United Therapeutics Corporation presently has an average rating of “Hold” and a consensus target price of $134.50.
WARNING: “United Therapeutics Corporation (UTHR) Receiving Somewhat Favorable News Coverage, Report Shows” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/09/united-therapeutics-corporation-uthr-receiving-somewhat-favorable-news-coverage-report-shows.html.
In other news, Director Raymond Dwek sold 3,490 shares of United Therapeutics Corporation stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $131.71, for a total value of $459,667.90. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Martine A. Rothblatt sold 1,238 shares of United Therapeutics Corporation stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $130.20, for a total value of $161,187.60. Following the completion of the transaction, the chief executive officer now owns 1,378 shares in the company, valued at approximately $179,415.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,178 shares of company stock worth $3,289,427. Company insiders own 7.80% of the company’s stock.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.